Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past three months, 11 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ:CRNX), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased by 13.27% to $69.82. Despite positive analyst sentiment, the company faces significant financial challenges, including a 76.11% decline in revenue growth and negative net margins.
June 28, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Crinetics Pharmaceuticals has received mixed but generally positive analyst ratings, with an average 12-month price target increase of 13.27%. However, the company faces significant financial challenges, including a 76.11% decline in revenue growth and negative net margins.
While analysts have shown a generally positive sentiment towards CRNX, reflected in the increased price targets, the company's significant financial challenges, including a steep decline in revenue growth and negative net margins, balance out the short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100